Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:28:03.244Z.
Calculation as of: 2026-10-06T16:28:03.244Z.
Quote observation: 2026-10-06T16:25:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a3ccde1bd0df5c55ebc0148063105fff0bf751cb52a3071af3e3331f6001fbe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$486.60M
EV/EBIT Ratio
14.95x
TTM Avg
10.51x
3Y Avg
8.16x
5Y Avg
8.11x
Market Cap
$473.46M
EV/EBIT Ratio
N/A
TTM Avg
5.92x
3Y Avg
17.76x
5Y Avg
17.76x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $495.09M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $495.50M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $501.13M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.60M | 14.95x | 10.51x | 8.16x | 8.11x |
| 908 Devices Inc. (MASS)vs › | $508.33M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $479.72M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $474.59M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $473.46M | N/A | 5.92x | 17.76x | 17.76x |
| Kamada Ltd. (KMDA)vs › | $473.09M | 16.36x | 15.53x | 17.24x | 21.68x |
| Crescent Biopharma, Inc. (CBIO)vs › | $513.04M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
